News -
Check out the posts below to learn the latest updates on our progress
- July 6 2022EXUMA Biotech Announces Participation in the In Vivo Engineering of Therapeutic Cells SummitPRNewswire
- June 21 2022Dr. Sid Kerkar talks to OncologyTube about EXUMA’s rPOC SC and in vivo GCAR programsOncologyTube
- April 11 2022Dr. Sid Kerkar talks to VJHemOnc at AACR 2022 about rPOC SC
VJHemOnc - April 8 2022In vivo delivery of a novel CD3-targeted Lentiviral Vector generates CD19 CAR-T cells in two different humanized mouse models and results in complete B cell depletion
AACR 2022 - April 8 2022Generation of tertiary lymphoid structures and CD3pos CD8pos CD56pos NKG2Dpos CAR TaNK cells following subcutaneous injection of CD3-directed lentiviral vector-loaded PBMC
AACR 2022 - March 15 2022EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual MeetingPRNewswire
- December 21 2021EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene TherapiesPRNewswire
- September 22 2021EXUMA Biotech to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare ConferencePRNewswire
- August 2 2021Building Scientific Trust Virtually
Life Science Leader - April 9 2021Subcutaneous injection of total nucleated cells rapidly isolated following four-hour peripheral whole blood exposure to CD3-directed CAR-T lentiviruses with a synthetic driver results in robust CAR-T proliferation and anti-tumor immunity
AACR Annual Meeting 2021